Genes and scans predict response to immunotherapy and targeted therapy for advanced sarcoma
Part of Bones, joints & muscles, Cancer, Immune system & allergy clinical trials.
This trial is testing whether a combination of two drugs—a targeted therapy (surufatinib) and an immunotherapy (envafolimab)—can help people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery. Researchers will also use a person's genetic information and scans to see if they can predict who will benefit the most.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a type of soft tissue sarcoma that cannot be removed by surgery or has spread to other parts of the body. Certain types like bone cancer or GIST are not included.
- You must be willing to receive the two study drugs (surufatinib and envafolimab) and have no medical reasons that would prevent you from taking them.
- Your tumor must be measurable on a scan (like a CT or MRI).
- You must be able to provide a sample of your tumor tissue (from a previous biopsy or a new one).
- You must have a performance status of 0, 1, or 2, meaning you are up and about at least half the day.
- Your kidney, liver, and blood clotting functions must be within a certain range, and your heart must be healthy enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests trabectedin plus ipilimumab and nivolumab in people with advanced soft-tissue sarcoma that has already been treated. It aims to see how well this combination works and how safely it can be given.
This trial tests a new immunotherapy drug (envafolimab) combined with two chemotherapy drugs (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior treatment. The goal is to see if this combination is safe and effective.
This trial tests two newer drugs—surufatinib, which cuts off blood supply to tumors, and envafolimab, which helps your immune system attack cancer cells—for people with advanced soft tissue sarcoma who have already tried other treatments. The goal is to see if this combination can help shrink tumors or slow their growth.
This trial tests a combination of a PARP inhibitor drug, targeted radiation (SBRT), and immunotherapy for people with advanced sarcoma that has spread. It aims to see if this triple therapy can shrink tumors or slow the disease.
This study tests a combination of two drugs (anlotinib and bempegaldesleukin) plus standard chemotherapy and radiation for people with advanced soft tissue sarcoma that has spread or can't be removed. The goal is to see if this combination helps shrink tumors and control the cancer.
This study tests whether giving radiation, chemotherapy, and immunotherapy together can control high-risk soft tissue sarcoma that is hard to remove or may come back after surgery. It may help by attacking cancer in different ways, including boosting the immune system.
Hear when a new Advanced Soft-tissue Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.